REVIEW ARTICLE

Biopharmaceutics in Drug Development: Mechanistic Insights into Absorption, Bioavailability, and Dosage Form Performance

Nadeem Siddiqui[1], Suryanarayana Veeravilli[2], Mohammed Nausheen[1], Kotikalapudi Karthik[1], Chaitanya Varada[1], Vaibhavi Vishnupriya[1], Chalapaka Srujana[1], Marla Soukyanand[1]

[1]Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India, [2]Department of Chemistry, Aditya University, Surampalem, Andhra Pradesh, India

Abstract

Biopharmaceutics is a fundamental discipline in drug development that examines the interplay between drug physicochemical properties, formulation design, and biological systems influencing drug absorption and bioavailability. This study highlights mechanistic insights into key processes such as dissolution, permeability, and first-pass metabolism that determine dosage form performance and therapeutic outcomes. The role of the biopharmaceutics classification system as a predictive framework for formulation optimization and bioequivalence assessment is discussed. Physiological factors affecting drug absorption, including gastrointestinal conditions, food effects, and interindividual variability, are critically examined. The study addresses advanced drug delivery approaches, including controlled-release systems and nanocarrier-based formulations, developed to overcome biopharmaceutic challenges associated with poorly soluble and poorly permeable drugs. In addition, the significance of predictive tools, such as *in vitro–in vivo* correlation and physiologically based pharmacokinetic modeling, in supporting rational formulation development and regulatory decision-making is emphasized. Overall, this review underscores the importance of biopharmaceutics as an integrative science that enhances drug development efficiency and ensures consistent therapeutic performance of pharmaceutical products.

Key words: Bioavailability, biopharmaceutics, dosage form design, drug absorption

INTRODUCTION

Biopharmaceutics is a fundamental discipline in drug development that focuses on understanding the relationship between the physicochemical properties of drug substances, dosage form design, and the *in vivo* performance of drugs.[1] It provides mechanistic insights into critical processes such as drug dissolution, solubility, permeability, absorption, distribution, and first-pass metabolism, all of which ultimately determine bioavailability and therapeutic efficacy.[2] A thorough understanding of these processes is essential for designing safe, effective, and reproducible pharmaceutical products. Over the past decades, biopharmaceutic concepts have evolved from empirical formulation approaches to mechanism-based strategies that integrate drug properties, physiological factors, and formulation variables.[3] The introduction of the biopharmaceutics classification system (BCS) has been a major milestone, enabling the categorization of drugs based on solubility and intestinal permeability and guiding formulation development, biowaiver decisions, and regulatory assessments. Similarly, the development of *in vitro–in vivo* correlation (IVIVC) and *in vitro–in vivo* extrapolation approaches has improved the ability to predict clinical performance using laboratory-based tests, reducing development time and cost.[4] Advances in analytical tools, computational modeling, and

Address for correspondence:
Nadeem Siddiqu, Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India.
E-mail: siddiqui@kluniversity.in

Received: 03-02-2026
Revised: 14-03-2026
Accepted: 23-03-2026

physiologically based pharmacokinetic (PBPK) modeling have further strengthened mechanistic understanding of drug absorption and disposition. These tools allow scientists to simulate complex biological environments, optimize dosage forms, and evaluate the impact of formulation changes on drug exposure.[5] In parallel, innovative delivery systems such as modified-release, lipid-based, and nanotechnology-enabled formulations have expanded the applicability of biopharmaceutic principles to poorly soluble and challenging drug candidates. Biopharmaceutics serves as a critical bridge between formulation science, pharmacokinetics, and clinical performance, enabling rational decision-making throughout the drug development lifecycle and supporting the development of high-quality, patient-centric medicines.[6]

DRUG ABSORPTION AND BIOAVAILABILITY

Drug absorption refers to the movement of a drug from its site of administration into systemic circulation, whereas bioavailability represents the fraction of the administered dose that reaches the bloodstream in unchanged form. These parameters are fundamental to therapeutic effectiveness, as insufficient absorption leads to reduced efficacy. Factors influencing absorption include drug solubility, permeability, formulation design, gastrointestinal motility, and first-pass metabolism. Oral drugs often face challenges such as enzymatic degradation and pH variations. Biopharmaceutics evaluates these barriers and provides strategies to overcome them. Understanding bioavailability also helps in comparing different formulations and routes of administration, which is essential for generic drug development and therapeutic substitution.[7]

BCS

The BCS categorizes drugs based on their solubility and intestinal permeability into four classes, as mentioned in Table 1. This system helps predict *in vivo* drug performance and guides formulation strategies. BCS Class I drugs show high solubility and permeability and are easily absorbed. Class II drugs have low solubility but high permeability, requiring solubility enhancement techniques. Class III drugs are highly soluble but poorly permeable, often needing permeability enhancers. Class IV drugs present challenges in both solubility and permeability, making formulation complex. Regulatory agencies use BCS to grant biowaivers, reducing the need for *in vivo* bioequivalence studies, thus accelerating drug development.[8]

MECHANISMS OF DRUG TRANSPORT

Drugs cross biological membranes through several mechanisms, including passive diffusion, facilitated diffusion, active transport, and endocytosis. Passive diffusion is the most common route and depends on the concentration gradient and lipophilicity. Carrier-mediated transport involves specific transporters that can enhance or limit absorption.[9] Efflux transporters such as P-glycoprotein can reduce oral bioavailability by pumping drugs back into the intestinal lumen. Endocytosis is important for macromolecules and nanoparticle-based systems. Understanding these transport mechanisms helps in designing drug molecules and formulations that can efficiently cross biological barriers and achieve desired therapeutic levels.[10]

ROLE OF DOSAGE FORM DESIGN

Dosage form design is a critical aspect of biopharmaceutics as it determines how a drug is released, dissolved, and absorbed. The choice of excipients, particle size, manufacturing method, and release mechanism significantly influences drug performance. Immediate-release formulations aim for rapid absorption, while controlled-release systems maintain steady plasma levels over extended periods. Advanced delivery systems such as nanoparticles, liposomes, and microspheres improve solubility, stability, and targeting. Biopharmaceutics provides the scientific framework for selecting and optimizing dosage forms to enhance therapeutic efficacy and patient compliance.[11]

PHYSIOLOGICAL FACTORS AFFECTING DRUG ABSORPTION

Physiological conditions such as gastric emptying time, intestinal motility, pH, enzyme activity, and the presence of food can significantly affect drug absorption. Variability in these factors leads to interindividual differences in drug response. Disease states, age, and genetic differences also play a role in altering absorption and metabolism. The gastrointestinal environment is particularly complex, as it changes dynamically throughout the day. Biopharmaceutics studies these variables to predict drug behavior under different physiological conditions and helps in designing robust formulations that perform consistently across patient populations.[12]

IVIVC

IVIVC is a predictive tool that establishes a relationship between *in vitro* dissolution data and *in vivo* drug absorption.[13] It is widely used to optimize formulations and reduce the need for extensive clinical studies. A strong IVIVC allows manufacturers to make formulation or process changes without repeating bioequivalence studies. Regulatory authorities encourage IVIVC as part of quality by design (QbD) approaches. Biopharmaceutics plays a central role in developing and validating IVIVC models, which improve efficiency in drug

Table 1: Biopharmaceutics classification system

BCS class	Solubility	Permeability	Absorption characteristics	Formulation challenges	Typical formulation strategies	Regulatory implications
Class I	High	High	Rapid and complete absorption	Minimal	Conventional immediate-release dosage forms	Eligible for biowaivers based on dissolution
Class II	Low	High	Dissolution-limited absorption	Poor aqueous solubility	Solubility enhancement, nanoparticles, solid dispersions	Conditional biowaivers; dissolution critical
Class III	High	Low	Permeability-limited absorption	Low membrane permeability	Permeation enhancers, absorption modifiers	Biowaivers are possible with strict excipient control
Class IV	Low	Low	Poor and variable absorption	Both solubility and permeability limitations	Advanced delivery systems, lipid carriers, and nanotechnology	Not eligible for biowaivers; extensive *in vivo* studies required



Figure 1: Schematic representation of *in vitro–in vivo* correlation

development and ensure consistent product quality.[14] Figure 1 depicts the establishment of IVIVC by linking dissolution data obtained from laboratory testing with *in vivo* pharmacokinetic parameters such as plasma concentration, C_{max}, and area under the curve. The predictive model enables estimation of *in vivo* drug performance from *in vitro* results, supporting formulation optimization and regulatory decisions.[15]

PBPK MODELING

PBPK models simulate drug absorption, distribution, metabolism, and excretion using mathematical representations of human physiology.[16] These models integrate drug-specific data with anatomical and physiological parameters to predict plasma concentration–time profiles. PBPK modeling is increasingly used in regulatory submissions to support dose selection, pediatric extrapolation, and drug–drug interaction assessment. Biopharmaceutics provides essential input data such as solubility, permeability, and dissolution rates for these models. The use of PBPK enhances prediction accuracy and reduces reliance on animal and human studies.[17]

REGULATORY IMPORTANCE

Biopharmaceutics plays a vital role in regulatory science, especially in bioequivalence evaluation, generic drug approval, and post-approval changes. Regulatory agencies require detailed biopharmaceutic data to ensure consistent product performance. Concepts such as biowaivers, BCS-based approval, and dissolution testing are grounded in biopharmaceutic principles. QbD approaches also rely on understanding the relationship between formulation, process, and clinical performance. A strong biopharmaceutic foundation ensures compliance with regulatory standards and helps bring safe and effective medicines to market efficiently.[18]

FUTURE TRENDS

The future of biopharmaceutics is shaped by advances in nanotechnology, artificial intelligence, and personalized medicine. Smart drug delivery systems capable of responding to biological signals are under development.[19] AI and machine learning tools are improving the prediction of

drug absorption and formulation performance. The growing understanding of microbiome–drug interactions is opening new research avenues.[20] In addition, 3D cell models and organ-on-chip technologies are improving *in vitro* prediction of human responses. These innovations are expanding the scope of biopharmaceutics and strengthening its role in modern drug development.[21]

CONCLUSION

Biopharmaceutics serves as a cornerstone of modern drug development by integrating drug properties, formulation design, and biological factors to predict and optimize therapeutic performance. A mechanistic understanding of absorption, bioavailability, and dosage form behavior enables the rational design of effective and safe pharmaceutical products. Advances in formulation technologies, predictive modeling, and regulatory science have significantly strengthened the translational value of biopharmaceutics. As drug molecules become increasingly complex, the role of biopharmaceutics in guiding formulation strategies, ensuring product quality, and supporting regulatory decisions will continue to expand. Ultimately, biopharmaceutic principles are essential for improving drug development efficiency and achieving consistent clinical outcomes.

REFERENCES

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. Pharm Res 1995;12:413-20.
2. Dressman JB, Reppas C. *In vitro-in vivo* correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11 Suppl 2:S73-80.
3. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, *et al*. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 2002;19:921-5.
4. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998;87:403-10.
5. Sugano K. Fundamentals of *in vitro-in vivo* correlation: Mechanistic understanding of drug absorption. J Pharm Sci 2009;98:3066-77.
6. Kesisoglou F, Panmai S, Wu Y. Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631-44.
7. Atkinson AJ Jr., editor. Principles of clinical pharmacology, Drug absorption and bioavailability: Rate and extent of drug absorption and its determinants. In: Atkinson's Principles of Clinical Pharmacology. 4th ed., Ch. 4. Netherlands: Elsevier; 2022. p. 43-59.
8. Roberts AG. The structure and mechanism of drug transporters. Methods Mol Biol 2021;2342:193-234.
9. Katsura T, Inui KI. Intestinal absorption of drugs mediated by drug transporters: Mechanisms and regulation. Drug Metab Pharmacokinet 2003;18:1-15.
10. Lin JH, Yamazaki M. Role of transporters in drug absorption, distribution, and elimination. Drug Metab Pharmacokinet 2003;18:309-24.
11. Kochkina N, Terekhova I. Design of dosage forms with improved biopharmaceutical properties. Pharmaceutics 2024;16:69.
12. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 2020;11:524.
13. Emami J. *In vitro - in vivo* correlation: From theory to applications. J Pharm Pharm Sci 2006;9:169-89.
14. Patel R, Patel A. *In vivo-in vitro* correlation (IVIVC) in drug development: bridging preclinical and clinical outcomes for regulatory approvals. World J Adv Res Rev 2024;22:2311-28.
15. Davanço MG, Campos DR, Carvalho PO. *In vitro - in vivo* correlation in the development of oral drug formulation: A screenshot of the last two decades. Int J Pharm 2020;580:119210.
16. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73.
17. Sager JE, Yu J, Ragueneau Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: A systematic review of published models, applications, and model verification. Drug Metab Dispos 2015;43:1823-37.
18. Jiang W, Kim S, Zhang X, Lionberger RA, Davit BM, Conner DP, *et al*. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm 2011;418:151-60.
19. Forbes B, Goodacre L, Lansley AB, Martin AR, Palmer H, Patterson C, *et al*. Advances in nasal biopharmaceutics to support product development and therapeutic needs. Pharmaceutics 2025;17:1321.
20. Gao J, Karp JM, Langer R, Joshi N. The future of drug delivery. Chem Mater 2023;35:359-74.
21. Ali HB, Khan MB. Artificial intelligence driven strategies and modern biopharmaceutic innovations: Overcoming barriers in drug development. J Exp Pharmacol 2025;17:125-45.

Source of Support: Nil. **Conflicts of Interest:** None declared.